Author
Listed:
- Mu-Peng Li
(Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China)
- Xiao-Lei Hu
(Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China)
- Yong-Long Yang
(Haikou People’s Hospital and Affiliated Haikou Hospital of Xiangya Medical School, Central South University, Haikou 570311, China)
- Yan-Jiao Zhang
(Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China)
- Ji-Peng Zhou
(Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China)
- Li-Ming Peng
(Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha 410008, China)
- Jie Tang
(Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China)
- Xiao-Ping Chen
(Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China)
Abstract
Left ventricular remodeling is an essential risk factor contributing to the pathogenesis of chronic heart failure (CHF). Basigin (BSG) promotes cardiovascular inflammation and myocardial remodeling processes by induction of extracellular matrix metalloproteinases and inflammatory cytokines. BSG rs8259 polymorphism was associated with BSG expression and risk of acute coronary syndrome. Therefore, we investigated whether rs8259 polymorphism contributes to risk and prognosis of CHF in Chinese patients. In total 922 adult patients with CHF and 1107 matched healthy controls were enrolled. BSG rs8259 polymorphism was genotyped using PCR-restriction fragment length polymorphism. Whole blood BSG mRNA expression data from Genotype-Tissue Expression project was accessed. Evaluation of follow-up data was performed in only 15.2% (140) of the patients with CHF. BSG rs8259 TT genotype was associated with a decreased risk of CHF (OR = 0.83, 95% CI = 0.72–0.96, p = 0.010), especially in patients with hypertension (OR = 0.80, 95% CI = 0.68–0.95, p = 0.011) and coronary heart disease (OR = 0.81, 95% CI = 0.69–0.96, p = 0.013) after adjustment for multiple cardiovascular risk factors. Rs8259 T allele was associated with decreased BSG mRNA in whole blood from 338 healthy normal donors ( p = 1.31 × 10 −6 ). However, rs8259 polymorphism failed to exhibit an association with cardiovascular mortality ( p = 0.283). BSG rs8259 polymorphism may contribute to decreased risk of CHF in a Chinese Han population.
Suggested Citation
Mu-Peng Li & Xiao-Lei Hu & Yong-Long Yang & Yan-Jiao Zhang & Ji-Peng Zhou & Li-Ming Peng & Jie Tang & Xiao-Ping Chen, 2017.
"Basigin rs8259 Polymorphism Confers Decreased Risk of Chronic Heart Failure in a Chinese Population,"
IJERPH, MDPI, vol. 14(2), pages 1-11, February.
Handle:
RePEc:gam:jijerp:v:14:y:2017:i:2:p:211-:d:91040
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:14:y:2017:i:2:p:211-:d:91040. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.